Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Researchers Study Flu Proteins to Identify Vulnerabilities

February 14, 2011 7:13 am | News | Comments

Each year, people everywhere prepare for flu season. Some will get the flu vaccine, some take vitamin supplements, some launch a vigorous handwashing campaign, while others take an entirely different approach: nuclear magnetic resonance.

TOPICS:

PROLOR Study to Be Completed by Mid-Year

February 14, 2011 7:08 am | News | Comments

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, reported that patient enrollment and dosing in the Phase 2 trial of its long-acting version of human growth hormone (hGH-CTP) are proceeding according to plan.

TOPICS:

Tarsa Finishes Phase 3 Calcitonin Trial

February 14, 2011 7:05 am | News | Comments

Tarsa Therapeutics, Inc. announced completion of its global Phase 3 ORACAL trial testing the company’s once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. Results from the ORACAL trial are expected in early spring.

TOPICS:
Advertisement

From HCS Image to Info

February 14, 2011 6:42 am | by Tim Moran, Director of Imaging; Accelrys, Inc., San Diego, Calif. | Articles | Comments

Image analysis is critical to understanding the results of large-scale cell-based screening assays used in drug discovery. High-content screening methods present challenges for extracting, analyzing, integrating, and sharing assay results.

TOPICS:

Particle Imaging and Analysis System

February 11, 2011 7:36 am | Product Releases | Comments

The FlowCAM Front-Fill Illumination particle imaging and analysis system from Fluid Imaging Technologies is the first to feature bidirectional front and back lighting, which illuminates the surfaces of opaque particles and reveals their true colors and textures.

TOPICS:

SEC-LS Detector

February 11, 2011 7:33 am | Product Releases | Comments

Malvern Instruments has launched the Zetasizer µV with OmniFACE and OmniSEC, a SEC-LS (size exclusion chromatography - light scattering) detector package dedicated to protein analysis.

TOPICS:

Vanda Profits Up $11.4M Over Previous Year

February 11, 2011 7:23 am | News | Comments

Vanda Pharmaceuticals Inc. said it turned a profit in the fourth quarter on reduced expenses, including lower costs related to its schizophrenia drug Fanapt.

TOPICS:

Momenta Earns $36.3M in 4th

February 11, 2011 7:12 am | News | Comments

Momenta Pharmaceuticals Inc. said it turned a fourth-quarter profit and achieved profitability for the first time in 2010 as a generic version of the anti-clotting drug Lovenox pushed revenue growth.

TOPICS:
Advertisement

Preladenant Reduces Down Time in Parkinson's Patients

February 11, 2011 7:07 am | News | Comments

Preladenant, a non-dopaminergic medication, reduces off time in patients with Parkinson's disease receiving standard dopamine therapy. The findings suggest that preladenant may offer a new supplemental treatment with fewer complications.

TOPICS:

Discovery May Lead to Alzheimer's Treatments

February 11, 2011 7:01 am | News | Comments

Scientists have made a discovery that has the potential for use in the early diagnosis and eventual treatment of plaque-related diseases such as Alzheimer's disease and Type 2 diabetes.

TOPICS:

TB-402 Performs Well in VTE Trial

February 11, 2011 6:51 am | News | Comments

BioInvent International AB and co-development partner ThromboGenics NV have announced positive results of a TB-402 Phase 2 trial, evaluating the product’s efficacy and safety for the prevention of venous thromboembolism after orthopaedic surgery.

TOPICS:

Juvista Fails Late-Stage Trial

February 11, 2011 6:46 am | News | Comments

Renovo Group plc, which develops drugs to reduce scarring, improve wound healing, and enhance tissue regeneration, announces that its first EU Phase 3 trial for Juvista in scar revision surgery (REVISE) did not meet its primary or secondary endpoints.

TOPICS:

Shire Profits Drop On Costs

February 11, 2011 6:42 am | News | Comments

Irish drug developer Shire Plc. said its fourth-quarter profit fell on higher costs, but the results met Wall Street expectations. The company earned $165.1 million, down from $174.3 million.

TOPICS:

Lilly Names New Cancer President

February 11, 2011 6:39 am | News | Comments

Eli Lilly and Co. named company insider Sue Mahony as president of its cancer drug business. The change is effective immediately. Mahony has worked at Eli Lilly for about 10 years, the company said.

TOPICS:

Principal Investigator System Enables CROs to Improve Bioanalytical Study Management

February 10, 2011 10:26 am | by Richard LeLacheur, Vice President, PharmaNet, Princeton, NJ | Articles | Comments

In order to ensure smooth operation during bioanalytical studies, a novel model, where a principal investigator with direct control over the entire study is the core of the project, has been developed.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading